KRAS and Miyoshi myopathy: Additionally, about 30% of patients with MM harbor mutations in the mitogen-activated protein kinase (MAPK) pathway, which includes the KRAS, NRAS and BRAF genes, making it the most affected signaling pathway and, therefore, an appealing target for biomarker exploration (17).